A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.

Autor: Feng J; Sino-French Hoffmann Institute, State Key Laboratory of Respiratory Disease, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China; Guangzhou National Laboratory, Guangzhou Bio-Island, Guangzhou 510005, China; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China., Du Y; Sino-French Hoffmann Institute, State Key Laboratory of Respiratory Disease, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China., Chen L; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China., Su W; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China., Wei H; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China., Liu A; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China., Jiang X; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China., Guo J; Guangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangzhou 510900, China., Dai C; Guangzhou Bay Area Institute of Biomedicine, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, Guangzhou 510900, China., Xu Y; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China. Electronic address: xuyuhua@gdscvc.com., Peng T; Sino-French Hoffmann Institute, State Key Laboratory of Respiratory Disease, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China; Guangdong South China Vaccine Co., Ltd., Guangzhou 510530, China. Electronic address: gzhpeng@outlook.com.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2024 Sep 17; Vol. 42 (22), pp. 126008. Date of Electronic Publication: 2024 Jun 03.
DOI: 10.1016/j.vaccine.2024.05.056
Abstrakt: Globally, influenza poses a substantial threat to public health, serving as a major contributor to both morbidity and mortality. The current vaccines for seasonal influenza are not optimal. A novel recombinant hemagglutinin (rHA) protein-based quadrivalent seasonal influenza vaccine, SCVC101, has been developed. SCVC101-S contains standard dose protein (15μg of rHA per virus strain) and an oil-in-water adjuvant, CD-A, which enhances the immunogenicity and cross-protection of the vaccine. Preclinical studies in mice, rats, and rhesus macaques demonstrate that SCVC101-S induces robust humoral and cellular immune responses, surpassing those induced by commercially available vaccines. Notably, a single injection with SCVC101-S can induce a strong immune response in macaques, suggesting the potential for a standard-dose vaccination with a recombinant protein influenza vaccine. Furthermore, SCVC101-S induces cross-protection immune responses against heterologous viral strains, indicating broader protection than current vaccines. In conclusion, SCVC101-S has demonstrated safety and efficacy in preclinical settings and warrants further investigation in human clinical trials. Its potential as a valuable addition to the vaccines against seasonal influenza, particularly for the elderly population, is promising.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Authors from Guangdong South China Vaccine Co. Ltd. are current or past employees of this for-profit organization. The authors have submitted patent applications related to the work described herein.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: